BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
85.02 ^USD	+1.32%		+4.38%	-11.82%

Jul. 01	BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 3000E Growth Index	CI
Jul. 01	BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Defensive Index	CI

BioMarin Pharmaceutical Inc. Reaffirms Earnings Outlook for the Year 2017

January 08, 2018 at 11:30 am EST

BioMarin Pharmaceutical Inc. reaffirmed earnings outlook for the year 2017. For the period, the company expects that it would be at the top of the range – - so $1,290 million to $1,320 million.

Latest news about BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 3000E Growth Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Defensive Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Growth Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Midcap Growth Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 3000 Growth Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Value-Defensive Index	Jun. 30	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Wells Fargo Adjusts BioMarin Pharmaceutical Price Target to $115 From $110, Maintains Overweight Rating	Jun. 27	MT
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P 1000	Jun. 23	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P 400 - Biotechnology	Jun. 23	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P 400 Health Care	Jun. 23	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P Composite 1500	Jun. 23	CI
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to S&P 400	Jun. 23	CI
Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion	Jun. 10	DJ
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24	Jun. 10	MT
BioMarin Pharmaceutical Reports New Data Affirming Long-Term Safety, Efficacy of Roctavian	Jun. 07	MT
BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing	May. 31	MT
Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	May. 17	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	May. 15
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing	May. 13	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	May. 06	MT
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04	CI
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	Apr. 29	MT

Chart BioMarin Pharmaceutical Inc.

Duration

Period

More charts

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

85.02 USD

Average target price

109.4 USD

Spread / Average Target

+28.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
CSL LIMITED	+6.96%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.29%	42.63B
BIOGEN INC.	-11.09%	33.5B
UCB	+82.32%	29.77B
INCYTE CORPORATION	+1.39%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.13%	11.55B
ALTEOGEN INC.	+176.65%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+6.74%	9.2B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.52%	8.98B

Biopharmaceuticals